- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03468465
Peripheral Transcutaneous Neuromodulation of the Post-tibial Nerve for Solifenacin 10 mg. Hyperactive Bladder Syndrome (SOLITENS)
August 1, 2018 updated by: Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Peripheral Transcutaneous Neuromodulation of the Post-tibial Nerve (T-PTNS) for Solifenacin 10 mg. in the Treatment of Hyperactive Bladder Syndrome: no Inferiority Phase IV Randomized Clinical Trial
- To determine if the T-PTNS is not inferior in the short term (3 months) to one of the usual pharmacological treatments (Solifenacin) in the treatment of hyperactive bladder syndrome and with respect to the percentage of patients that improve 50% any of the 3 signs (Urinary frequency, diurnal / nocturnal frequency, urgency and urinary incontinence).
- To determine prognostic factors associated with insufficient improvement (less than 50% in the 3 main signs of hyperactive bladder syndrome (urinary frequency, urgency and urinary incontinence frequency) after treatment with T-PTNS and Solifenacin.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Patients will be randomized to receive the usual standard treatment with Solifenacin or treatment based on peripheral unilateral transcutaneous neuromodulation of the posterior tibial nerve .
Study Type
Interventional
Enrollment (Anticipated)
110
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Murcia
-
El Palmar, Murcia, Spain, 30120
- Hospital Clínico Universtario Virgen de la Arrixaca
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Women> 18 years, diagnosed with hyperactive bladder syndrome for at least 6 months of evolution and who have taken Beta 3 agonists
Exclusion Criteria:
- Patients who can contribute biased information: have previously consumed and abandoned anticholinergic drugs due to lack of efficacy or side effects; Suffering from hyperactive bladder of neurogenic origin (multiple sclerosis, Parkinson's, spinal cord injury); Present cystocele or any pelvic organ prolapse> 2 according to Pelvic Organ Prolapse-Q classification
- Patients who may become worse with the interventions envisaged in the study: being a implantable automatic defibrillators; With cutaneous alterations in lower extremities that prevent the placement of electrodes on the surface; Women who are pregnant or who may be pregnant during the duration of the clinical trial (prior and at each evaluation visit urine Bhcg will be requested to rule out pregnancy) or patients who are not able to manage transcutaneous electrical neurostimulation on an outpatient basis ) Or patients in whom Solifenacin is contraindicated: urinary retention, severe gastrointestinal disorders (including toxic megacolon), myasthenia gravis, or narrow-angle glaucoma, and in patients at risk of these conditions as hypersensitive at first Active or to any of the excipients, undergoing hemodialysis, with moderate hepatic insufficiency or severe renal insufficiency or in simultaneous treatment with a potent inhibitor of CYP3A4, eg ketoconazole.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Medical device: Transcutaneous electrical neurostimulation
Medical device 4 weeks with daily sessions of 30 minutes
|
Treatment with T-PTNS will include a first induction period of 4 weeks with daily sessions of 30 minutes duration and performed at each subject's home (Monday through Friday, resting weekends) and a second recall period of 2 additional months, with a session every 4 weeks that will be held at the healthcare center.
In total there will be 20 sessions in the induction period and 2 in the recall period
Other Names:
|
ACTIVE_COMPARATOR: Solifenacin
10 mg tablet daily during 75 days maximum
|
10 mg tablet daily during 75 days maximum
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate whether treatment with T-PTNS is not less than 3 months compared to the current standard pharmacological treatments regarding the episodes of urgency, urinary frequency, incontinence and nocturia, all measured with the 3-day voiding diary
Time Frame: 12 weeks
|
3- day voiding diary
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: José David Jiménez Parra, MD, Hospital Rafael Méndez (Lorca, Murcia. SPAIN)
- Principal Investigator: María Luisa María Luisa, MD, Hospital Clínica Universitario Virgen de la Arrixaca (SPAIN)
- Principal Investigator: José Felix Escudero Bregante, MD, Hospital Clínico Universitario Virgen de la Arrixaca (SPAIN)
- Principal Investigator: Julián Oñate, MD, Hospital General Universitario Reina Sofía (SPAIN)
- Principal Investigator: Ana Isabel López López, MD, Hospital Clínico Universitario San Juan (SPAIN)
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 4, 2018
Primary Completion (ANTICIPATED)
March 1, 2019
Study Completion (ANTICIPATED)
March 1, 2019
Study Registration Dates
First Submitted
February 20, 2018
First Submitted That Met QC Criteria
March 15, 2018
First Posted (ACTUAL)
March 16, 2018
Study Record Updates
Last Update Posted (ACTUAL)
August 2, 2018
Last Update Submitted That Met QC Criteria
August 1, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Urologic Diseases
- Urinary Bladder Diseases
- Lower Urinary Tract Symptoms
- Urological Manifestations
- Neurologic Manifestations
- Urination Disorders
- Dyskinesias
- Urinary Bladder, Overactive
- Urinary Incontinence
- Hyperkinesis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Urological Agents
- Solifenacin Succinate
Other Study ID Numbers
- FFIS/2017/01/SLT
- 2017-000605-20 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Incontinence
-
University of New MexicoRecruitingUrinary Incontinence | Urge Incontinence | Stress Incontinence, FemaleUnited States
-
Juna d.o.o.CompletedFemale Stress Urinary Incontinence | Mixed Incontinence, Urge and Stress
-
University of California, San FranciscoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Stanford...CompletedUrinary Incontinence, Stress | Urge Incontinence | Urinary Stress Incontinence | Stress Incontinence, Urinary | Stress Incontinence | Stress Incontinence, Female | Urgency UrinaryUnited States
-
Ludwig-Maximilians - University of MunichUnknownIncontinence, Overactive Bladder, Stress Urinary IncontinenceGermany
-
San Diego Sexual MedicineRecruitingStress Urinary Incontinence | Urge IncontinenceUnited States
-
Copenhagen University Hospital at HerlevZealand University HospitalTerminatedStress Urinary Incontinence | Urge Urinary IncontinenceDenmark
-
Far Eastern Memorial HospitalRecruitingWomen With Stress Urinary IncontinenceTaiwan
-
ScitonCompletedUrinary Incontinence | Stress Urinary Incontinence | Urge IncontinenceUnited States
-
Université de SherbrookeRecruitingUrinary Incontinence | Urinary Stress Incontinence | Post-Prostatectomy Incontinence | Stress Incontinence, MaleCanada
-
University of ZurichCompletedStress Urinary Incontinence | Urge Urinary Incontinence
Clinical Trials on Neuro-Muscular Stimulators (NMS)
-
MedStar National Rehabilitation NetworkCompletedRehabilitation | Total Knee ArthroplastyUnited States
-
Riphah International UniversityCompletedKnee OsteoarthritisPakistan
-
Medical Corps, Israel Defense ForceAriel UniversityCompleted
-
Ulsan University HospitalWithdrawnDeglutition DisorderKorea, Republic of
-
University Hospital, BordeauxTerminatedAmyotrophic Lateral Sclerosis | ALSFrance
-
Policlinico HospitalUnknownResolution of Neuromuscular BlockadeItaly
-
Hospital Nacional Profesor Alejandro PosadasCompletedMuscle Weakness | Rehabilitation
-
Mercedes García de QuesadaCívitas-UGR Chair: Sustainability, Innovation and Development, Granada, SpainCompletedCompassion | Anxiety | Psychological Distress | Attention | Empathy | Creativity | Life Stress | Emotional IntelligenceSpain
-
Mercedes García de QuesadaCívitas-UGR Chair: Sustainability, Innovation and Development, Granada, Spain and other collaboratorsCompletedCompassion | Anxiety | Psychological Distress | Attention | Empathy | Creativity | Life Stress | Emotional IntelligenceSpain
-
SanofiCompletedInsomnia | Sleep Initiation and Maintenance DisordersCanada, United States, Australia